Torrent Pharmaceuticals draws up plan to reduce dependence on US

Company to draw 47% of revenue and 67% of Ebitda from Indian business by FY20

With Unichem in its kitty, Ahmedabad-based Torrent Pharmceuticals is likely to draw around 47 per cent of revenues from the domestic business by 2019-20, feel analysts. The company would draw most of its profits from India too - the Ebitda contribution from Indian business is expected to improve to 67 per cent by then, compared to 10 per cent share from the US. 

In 2016-17, the share of India business in Torrent's turnover was 34 per cent, while in 2017-18, the share is expected to rise to 38-40 per cent. As such Torrent Pharma is a strong player in the